Trial Profile

Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegapamodutide (Primary) ; Exenatide; Metformin
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors OPKO Health

Most Recent Events

19 Mar 2021 Metformin added in arms and interventions.
13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
30 Jun 2016 Results published in a joint media release by OPKO Health and Transition Therapeutics.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com